A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants with Overweight or Obese
Latest Information Update: 28 May 2026
At a glance
- Drugs BGM 0504 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 12 May 2026 Results presented in a BrightGene Bio-medical technology Media Release.
- 29 Nov 2024 New trial record